Menu
Medical Condition
Urology & Andrology
Urology & Andrology ICD-10: N20.0

Nephrolithiasis (Kidney Stones)

Clinical Criteria for Nephrolithiasis (Kidney Stones).

Medical Disclaimer
This condition guide is intended for educational and informational purposes only. It does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider regarding any symptoms or medical conditions.

Clinical Assessment & Protocol

Typical Presentation (HPI)

EN: Patient presents with acute onset of severe, colicky flank pain radiating to the groin/suprapubic region. Associated symptoms include nausea, vomiting, hematuria, and urinary urgency/frequency. Denies fever, chills, or dysuria. Pain intensity is rated [X]/10, intermittent, and exacerbated by movement. AR: يعاني المريض من ألم حاد ومغص في الخاصرة يمتد إلى منطقة الأربية/فوق العانة. تشمل الأعراض المصاحبة الغثيان، والقيء، وبيلة دموية، وإلحاح/تكرار في التبول. ينفي المريض وجود حمى، أو قشعريرة، أو عسر تبول. شدة الألم [X]/10، متقطع، ويزداد سوءاً مع الحركة.

General Examination

EN: General: Patient appears in acute distress, writhing in pain. Abdomen: Soft, non-distended, bowel sounds present. Tenderness: Significant unilateral costovertebral angle (CVA) tenderness on [Right/Left] side. No rebound tenderness or guarding. Genitourinary: External genitalia normal; no inguinal lymphadenopathy. AR: الحالة العامة: المريض يبدو في حالة إعياء شديد بسبب الألم. البطن: لين، غير منتفخ، أصوات الأمعاء مسموعة. الإيلام: وجود إيلام شديد في الزاوية الضلعية الفقرية (CVA) في الجانب [الأيمن/الأيسر]. لا يوجد إيلام ارتدادي أو تشنج عضلي. الجهاز البولي التناسلي: الأعضاء التناسلية الخارجية طبيعية؛ لا يوجد تضخم في الغدد الليمفاوية الأربية.

Treatment Protocol

EN: 1. Analgesia: NSAIDs (e.g., Ketorolac) or Opioids for breakthrough pain. 2. Antiemetics: Ondansetron as needed. 3. Medical Expulsive Therapy (MET): Tamsulosin 0.4mg daily. 4. Hydration: Encourage oral fluid intake (2-3L/day). 5. Follow-up: Strain urine for stone analysis; repeat imaging if symptoms persist or fever develops. AR: 1. مسكنات الألم: مضادات الالتهاب غير الستيرويدية (مثل كيتورولاك) أو المواد الأفيونية للألم الشديد. 2. مضادات القيء: أوندانسيترون عند الحاجة. 3. العلاج الطارد للحصوات (MET): تامسولوسين 0.4 ملغ يومياً. 4. الترطيب: تشجيع شرب السوائل (2-3 لتر/يومياً). 5. المتابعة: تصفية البول لتحليل الحصوة؛ إعادة التصوير إذا استمرت الأعراض أو حدثت حمى.

Patient Education

EN: You have been diagnosed with a kidney stone. Increase your daily water intake to ensure clear urine. Strain all urine to collect the stone for laboratory analysis. Return to the Emergency Department immediately if you develop high fever, chills, persistent vomiting, or inability to urinate. AR: تم تشخيص إصابتك بحصوات الكلى. يرجى زيادة كمية السوائل اليومية لضمان أن يكون البول صافياً. قم بتصفية البول لجمع الحصوة لتحليلها في المختبر. توجه إلى قسم الطوارئ فوراً إذا أصبت بحمى شديدة، أو قشعريرة، أو قيء مستمر، أو عدم القدرة على التبول.

Systemic & Specialized Examinations

Cardiovascular

EN: Unremarkable. Not routinely indicated or affected by this specific systemic pathology. AR: طبيعي. غير مطلوب روتينياً أو غير متأثر بهذا المرض الجهازي.

Respiratory

EN: Unremarkable. Not routinely indicated or affected by this specific systemic pathology. AR: طبيعي. غير مطلوب روتينياً أو غير متأثر بهذا المرض الجهازي.

Gastrointestinal

EN: System-specific examination reveals findings consistent with the clinical diagnosis. No signs of acute decompensation. AR: الفحص السريري الخاص بالنظام يُظهر نتائج متوافقة مع التشخيص. لا توجد علامات لتدهور حاد.

Neurological

EN: Unremarkable. Not routinely indicated or affected by this specific systemic pathology. AR: طبيعي. غير مطلوب روتينياً أو غير متأثر بهذا المرض الجهازي.

Dermatological

EN: Unremarkable. Not routinely indicated or affected by this specific systemic pathology. AR: طبيعي. غير مطلوب روتينياً أو غير متأثر بهذا المرض الجهازي.

Psychiatric

EN: Unremarkable. Not routinely indicated or affected by this specific systemic pathology. AR: طبيعي. غير مطلوب روتينياً أو غير متأثر بهذا المرض الجهازي.

OB/GYN

EN: Unremarkable. Not routinely indicated or affected by this specific systemic pathology. AR: طبيعي. غير مطلوب روتينياً أو غير متأثر بهذا المرض الجهازي.

Ophthalmic

EN: Unremarkable. Not routinely indicated or affected by this specific systemic pathology. AR: طبيعي. غير مطلوب روتينياً أو غير متأثر بهذا المرض الجهازي.

Dental

EN: Unremarkable. Not routinely indicated or affected by this specific systemic pathology. AR: طبيعي. غير مطلوب روتينياً أو غير متأثر بهذا المرض الجهازي.

Orthopedic & Trauma Assessments

Mechanism of Injury

EN: Unremarkable. Not routinely indicated or affected by this specific systemic pathology. AR: طبيعي. غير مطلوب روتينياً أو غير متأثر بهذا المرض الجهازي.

Gait & Posture

EN: Unremarkable. Not routinely indicated or affected by this specific systemic pathology. AR: طبيعي. غير مطلوب روتينياً أو غير متأثر بهذا المرض الجهازي.

Range of Motion

EN: Unremarkable. Not routinely indicated or affected by this specific systemic pathology. AR: طبيعي. غير مطلوب روتينياً أو غير متأثر بهذا المرض الجهازي.

Local Examination

EN: Unremarkable. Not routinely indicated or affected by this specific systemic pathology. AR: طبيعي. غير مطلوب روتينياً أو غير متأثر بهذا المرض الجهازي.

Special Tests

EN: Unremarkable. Not routinely indicated or affected by this specific systemic pathology. AR: طبيعي. غير مطلوب روتينياً أو غير متأثر بهذا المرض الجهازي.

Motor Power

EN: Unremarkable. Not routinely indicated or affected by this specific systemic pathology. AR: طبيعي. غير مطلوب روتينياً أو غير متأثر بهذا المرض الجهازي.

Sensory Profile

EN: Unremarkable. Not routinely indicated or affected by this specific systemic pathology. AR: طبيعي. غير مطلوب روتينياً أو غير متأثر بهذا المرض الجهازي.

Reflexes

EN: Unremarkable. Not routinely indicated or affected by this specific systemic pathology. AR: طبيعي. غير مطلوب روتينياً أو غير متأثر بهذا المرض الجهازي.

Peripheral Pulses

EN: Unremarkable. Not routinely indicated or affected by this specific systemic pathology. AR: طبيعي. غير مطلوب روتينياً أو غير متأثر بهذا المرض الجهازي.

Comprehensive Clinical Guide: Nephrolithiasis (Kidney Stones)

Nephrolithiasis, colloquially known as kidney stones, represents one of the most prevalent and debilitating conditions encountered in clinical urology and emergency medicine. It is a crystalline concretions process within the renal parenchyma, calyces, or pelvis, often migrating into the ureter, where they cause significant obstruction, pain, and potential renal injury. This guide serves as an authoritative clinical reference for practitioners, detailing the pathophysiology, diagnostics, and management of this complex metabolic disorder.


1. Clinical Definition and Etiology

Nephrolithiasis is defined as the formation of solid calculi (stones) from dissolved urinary minerals. It is a multifactorial disease resulting from an imbalance between urinary promoters and inhibitors of crystallization.

Etiological Classifications

The composition of kidney stones is highly variable and serves as a roadmap for metabolic investigation.

Stone Type Prevalence Primary Etiology
Calcium Oxalate 70–80% Hypercalciuria, hyperoxaluria, hypocitraturia
Calcium Phosphate 5–10% Distal Renal Tubular Acidosis (RTA), hyperparathyroidism
Uric Acid 5–10% Low urinary pH, high purine intake, gout
Struvite 5–10% Infection with urease-producing bacteria (e.g., Proteus)
Cystine <1% Genetic defect in renal cystine transport (Cystinuria)

2. Pathophysiology: The Mechanics of Stone Formation

The genesis of nephrolithiasis follows a rigorous physiochemical sequence known as the "Nucleation-Growth-Aggregation" model.

Phase I: Supersaturation

Urine becomes supersaturated with respect to the specific salt (e.g., calcium oxalate). This is influenced by:
* Low Urine Volume: Increasing concentration of solutes.
* pH Deviations: Alkaline urine promotes calcium phosphate; acidic urine promotes uric acid and cystine.
* Ionic Strength: Concentration of lithogenic ions.

Phase II: Nucleation and Epitaxy

Crystals form in the supersaturated urine. Heterogeneous nucleation occurs when crystals form on a pre-existing surface (e.g., Randall’s plaque—subepithelial calcium phosphate deposits on the renal papilla).

Phase III: Crystal Retention and Growth

For a stone to develop, the crystal must be retained within the renal tubule long enough to grow. This involves adhesion molecules such as osteopontin and prothrombin fragment 1, which facilitate the anchoring of crystals to the renal epithelial cells.


3. Clinical Presentation and Staging

Standard Presentation

The classic presentation is renal colic, characterized by:
* Acute Onset: Severe, cramping flank pain radiating to the groin or scrotum/labia.
* Autonomic Symptoms: Nausea, vomiting, and diaphoresis due to the severity of pain.
* Hematuria: Gross or microscopic blood in the urine due to mucosal abrasion.

Clinical Staging (Obstruction Grading)

Clinicians must categorize the severity based on the risk of complications:
1. Uncomplicated: Stone <5mm, no infection, no renal failure, pain controlled.
2. Complicated: Stone >6mm, intractable pain, persistent vomiting, or signs of urosepsis (fever, tachycardia, hypotension).
3. High-Risk Patient: Solitary kidney, transplant kidney, or bilateral obstruction (requires emergent intervention).


4. Differential Diagnosis

The clinician must rule out "mimickers" that present with acute abdominal or flank pain:
* Gastrointestinal: Appendicitis, cholecystitis, diverticulitis, bowel obstruction.
* Vascular: Abdominal Aortic Aneurysm (AAA) rupture (critical rule-out in older patients).
* Gynecological: Ectopic pregnancy, ovarian torsion, pelvic inflammatory disease (PID).
* Musculoskeletal: Radiculopathy, muscle strain.


5. Diagnostic Testing Protocols

Gold Standard: Non-Contrast CT (NCCT)

A low-dose helical CT of the abdomen and pelvis is the diagnostic modality of choice. It provides 95–98% sensitivity and specificity for stone detection, size, and location.

Ancillary Tests

  • Urinalysis: Check for pH, hematuria, nitrites, and leukocyte esterase (to rule out UTI).
  • Basic Metabolic Panel: Assess Creatinine/BUN to determine if renal function is impaired.
  • KUB (Kidney-Ureter-Bladder) X-ray: Useful for monitoring radiopaque stones (calcium) over time.
  • Ultrasound: Preferred for pregnant patients or pediatrics to avoid radiation.

6. Management and Clinical Indications

Conservative Management (Medical Expulsive Therapy)

For stones <5mm, spontaneous passage is likely.
* Hydration: Goal of 2.5L output per day.
* Analgesia: NSAIDs (e.g., Ketorolac) are first-line for renal colic due to inhibition of prostaglandin-mediated ureteral contraction.
* Alpha-blockers: Tamsulosin 0.4mg daily to relax the ureteral smooth muscle and facilitate passage.

Surgical Intervention Indications

  • Failure to pass after 4–6 weeks.
  • Intractable pain or nausea.
  • Signs of infection (fever).
  • Renal insufficiency or obstruction of a solitary kidney.
Intervention Mechanism
Shock Wave Lithotripsy (SWL) External acoustic waves fragment the stone.
Ureteroscopy (URS) Endoscopic access to the stone with laser lithotripsy.
Percutaneous Nephrolithotomy (PCNL) Direct surgical access to the kidney for large staghorn calculi.

7. Risks and Contraindications

  • Contraindications for SWL: Pregnancy, uncorrected coagulopathy, untreated UTI, or distal obstruction.
  • Risks of Surgical Intervention: Ureteral injury, perforation, sepsis, and hematoma.
  • Chronic Risks: Recurrent nephrolithiasis can lead to Chronic Kidney Disease (CKD) and permanent renal scarring (nephrocalcinosis).

8. Long-Term Prognosis and Prevention

Prevention is predicated on the specific metabolic profile of the patient.
* Calcium Oxalate: Increase fluids, moderate calcium intake (do not restrict), reduce animal protein, and reduce oxalate-rich foods (spinach, nuts, chocolate).
* Uric Acid: Alkalinize urine (potassium citrate), lower purine intake.
* Struvite: Aggressive management of underlying chronic urinary tract infections.


9. Frequently Asked Questions (FAQ)

1. Is there a "best" position for passing a stone?

No specific position has been proven to expedite passage; however, remaining mobile and well-hydrated is clinically recommended.

2. Can I drink coffee?

Moderate caffeine intake is generally acceptable, but excessive intake can act as a diuretic and increase calcium excretion. Water remains the superior choice.

3. What is a "Staghorn Calculus"?

It is a large, branched stone that fills the renal pelvis and calyces, typically composed of struvite, necessitating surgical removal.

4. Why does my pain radiate to my groin?

The nerves innervating the ureter share the same spinal cord segments (T11–L2) as the nerves supplying the genitalia, leading to "referred pain."

5. Are all kidney stones visible on X-ray?

No. Uric acid stones and certain medication-induced stones (e.g., Indinavir) are radiolucent.

6. Does drinking lemon water help?

Yes. Lemons contain citrate, which is a potent inhibitor of calcium stone formation.

7. How long can I wait for a stone to pass?

Generally, 4 to 6 weeks is the limit, provided there is no infection or worsening renal function.

8. Is surgery always required for stones >5mm?

Not necessarily, but the likelihood of spontaneous passage decreases significantly as the stone size increases beyond 5mm.

9. Can kidney stones cause permanent damage?

Chronic, silent obstruction can lead to hydronephrosis and permanent loss of renal function in the affected kidney.

10. Will I get another stone?

Nephrolithiasis is a chronic condition. Without metabolic intervention, the recurrence rate is approximately 50% within 5–10 years.


Conclusion

Nephrolithiasis is a manageable but high-recurrence condition. Through rigorous metabolic evaluation, timely imaging, and appropriate surgical or medical intervention, the clinical impact of kidney stones can be significantly mitigated. Practitioners must emphasize lifestyle modification and hydration as the cornerstones of long-term patient health.

Treatment & Management Options

Share this guide: